Positive results from REMIX-1 and REMIX-2 on remilbrutinib could mean the beginning of a new class of chronic spontaneous urticaria therapy in about a decade.
The CDC is calling for more healthcare providers to become educated about alpha-gal syndrome (AGS), an allergy caused by tick bites that may have affected up to 450,000 people in the United States.